RT journal article
T1 The atheroma plaque secretome stimulates the mobilization of endothelial progenitor cells ex vivo
A1 Vega, Francisco M.
A1 Gautier, Violette
A1 Fernández Ponce, Cecilia Matilde
A1 Extremera, M.J.
A1 Altelaar, A.F.M.
A1 Millan, Jaime
A1 Tellez, Juan C.
A1 Hernandez-Campos, J.A.
A1 Conejero, Rosario
A1 Bolívar Pérez, Jorge
A1 Pardal, R.
A1 García Cózar, Francisco José
A1 Aguado Vidal, Enrique
A1 Heck, Albert J.R.
A1 Durán Ruiz, María del Carmen
A2 BiomedicinaBiotecnología y Salud Pública
K1 Endothelial progenitor cells
K1 Atherosclerosis
K1 Cell therapy
K1 Proteomics
K1 Cell migration
AB Endothelial progenitor cells (EPCs) constitute a promising alternative in cardiovascular regenerative medicinedue to their assigned role in angiogenesis and vascular repair. In response to injury, EPCs promote vascular remodelingby replacement of damaged endothelial cells and/or by secreting angiogenic factors over the damagedtissue. Nevertheless, such mechanisms need to be further characterized. In the current approach we have evaluatedthe initial response of early EPCs (eEPCs) from healthy individuals after direct contact with the factors releasedby carotid arteries complicated with atherosclerotic plaques (AP), in order to understand themechanisms underlying the neovascularization and remodeling properties assigned to these cells. Herein, wefound that the AP secretome stimulated eEPCs proliferation and mobilization ex vivo, and such increase was accompaniedby augmented permeability, cell contraction and also an increase of cell-cell adhesion in associationwith raised vinculin levels. Furthermore, a comparative mass spectrometry analysis of control versus stimulatedeEPCs revealed a differential expression of proteins in the AP treated cells, mostly involved in cell migration, proliferationand vascular remodeling. Some of these protein changeswere also detected in the eEPCs isolated fromatherosclerotic patients compared to eEPCs from healthy donors.We have shown, for the first time, that the AP released factors activate eEPCs ex vivo by inducing their mobilizationtogether with the expression of vasculogenic related markers. The present approach could be taken as aex vivo model to study the initial activation of vascular cells in atherosclerosis and also to evaluate strategieslooking to potentiate the mobilization of EPCs prior to clinical applications.
PB ELSEVIER SCI LTD
SN 0022-2828
YR 2017
FD 2017-02-20
LK http://hdl.handle.net/10498/30489
UL http://hdl.handle.net/10498/30489
LA eng
NO Instituto Nacional de Salud Carlos III (PI12-02680 y PI16-00784);  Prime XS-Consortium, EU Seventh Framework Programme(XS-000158) y European Research Council (ERC Starting Grant).  Andalucía Talent Hub Program_Andalusian Knowledge Agency, co-funded by the EU Seventh Framework Programme (COFUND – Grant n° 291780).
DS Repositorio Institucional de la Universidad de Cádiz
RD 08-nov-2026